Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease.

Autor:	Demirel M; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey.; Health Sciences Institute, Bezmialem Vakif University, Istanbul, Turkey., Köktaşoğlu F; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey., Özkan E; Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey., Dulun Ağaç H; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey., Gül AZ; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey., Sharifov R; Department of Radiology, Department of Gastroenterology, Bezmialem Vakıf University, Istanbul, Turkey., Sarıkaya U; Health Sciences Institute, Bezmialem Vakif University, Istanbul, Turkey.; Department of Medical Services and Techniques, Vocational School of Health Services, Bezmialem Vakıf University, Istanbul, Turkey., Başaranoğlu M; Department of Gastroenterology and Hepatology, Bezmialem Vakif University, Istanbul, Turkey., Selek Ş; Department of Medical Biochemistry, Bezmialem Vakif University Faculty of Medicine, Istanbul, Turkey.
Jazyk:	angličtina
Zdroj:	Scandinavian journal of gastroenterology [Scand J Gastroenterol] 2023 Jul-Dec; Vol. 58 (11), pp. 1344-1350. Date of Electronic Publication: 2023 Jun 20.
DOI:	10.1080/00365521.2023.2225667
Abstrakt:	Objectives: Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by the accumulation of excessive fat in the liver, which can lead to fibrosis and has an increasing prevalence. NAFLD requires non-invasive diagnostic biomarkers. While typically observed in overweight individuals, it can also occur in non-obese/non-overweight individuals. Comparative studies on non-obese NAFLD patients are scarce. This study aimed to conduct a using liquid chromatography-high resolution mass spectrometry (LC-MS/MS)-based metabolic profiling of non-obese NAFLD patients and healthy controls. Materials and Methods: The patient group consisted of 27 individuals with NAFLD, while the healthy control group included 39 individuals. Both groups were between 18 and 40 years old, had a BMI of less than 25 and had alcohol consumption less than 20 g/week for men and 10 g/week for women. Serum samples were collected and analyzed using LC-MS/MS. The data were analyzed using the TidyMass and MetaboAnalyst. Results: The LC-MS/MS analyses detected significant changes in D-amino acid metabolism, vitamin B6 metabolism, apoptosis, mTOR signaling pathway, lysine degradation, and phenylalanine metabolism pathways in non-obese NAFLD patients. Significant changes were also observed in the metabolites D-pantothenic acid, hypoxanthine, citric acid, citramalic acid, L-phenylalanine, glutamine, and histamine-trifluoromethyl-toluidide, β-hydroxymyristic acid, DL-Lactic acid, and 3-methyl-2-oxopentanoic. Overall, the study provides valuable insights into the metabolic changes associated with non-obese NAFLD patients and can contribute to the development of non-invasive diagnostic biomarkers for NAFLD. Conclusions: This study sheds light on the metabolic changes in non-obese NAFLD patients. Further research is needed to better understand the metabolic changes associated with NAFLD and to develop effective treatment options.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu